{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:32:37Z","timestamp":1764333157054,"version":"build-2065373602"},"reference-count":41,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives; Triple-negative breast cancer (TNBC) is associated with poor patient prognosis because of its multiple molecular features. Thus, more effective treatment for TNBC is urgently needed. This study determined the possible involvement of ERK1\/2 activation in cisplatin-induced cytotoxicity in TNBC by providing additional eribulin treatment. Materials and Methods; We investigated cell viability and apoptosis caused by eribulin, cisplatin, or co-treatment in HCC38, MDA-MB-231, and SKBR3 human breast cancer cells. Results; Cisplatin significantly lowered cell viability and caused high apoptotic cell death in all breast cancer cell lines. The viability of TNBC cells was significantly lower in the group co-treated with cisplatin and eribulin than in the cisplatin-only treatment group. Additional eribulin treatment significantly enhanced PARP cleavage and caspase-3 activity in cisplatin-treated TNBC cells. Moreover, cisplatin treatment activated ERK1\/2 in all breast cancer cell lines. The cisplatin and eribulin combination synergistically activated ERK1\/2 in TNBC cells compared with the cisplatin-only treatment. Administration of the ERK1\/2 inhibitor PD98059 increased the viability of TNBC cells treated with cisplatin plus eribulin. Conclusions; Eribulin could synergize the cytotoxic and apoptotic activities of cisplatin and increase ERK1\/2 activation, thus enhancing anti-cancer effects against TNBC cells.<\/jats:p>","DOI":"10.3390\/medicina58040547","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T01:03:01Z","timestamp":1650330181000},"page":"547","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1\/2 Activation"],"prefix":"10.3390","volume":"58","author":[{"given":"Hyemi","family":"Ko","sequence":"first","affiliation":[{"name":"Department of Surgery, Chungnam National University Hospital, Jung-gu, Daejeon 35015, Korea"},{"name":"Biomedical Research Institute, Chungnam National University Hospital, Jung-gu, Daejeon 35015, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myungsun","family":"Lee","sequence":"additional","affiliation":[{"name":"Biomedical Research Institute, Chungnam National University Hospital, Jung-gu, Daejeon 35015, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunyoung","family":"Cha","sequence":"additional","affiliation":[{"name":"Biomedical Research Institute, Chungnam National University Hospital, Jung-gu, Daejeon 35015, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyoung","family":"Sul","sequence":"additional","affiliation":[{"name":"Department of Surgery, Chungnam National University Hospital, Jung-gu, Daejeon 35015, Korea"},{"name":"Department of Surgery and Research Institute for Medicinal Sciences, Chungnam National University College of Medicine, Jung-gu, Daejeon 35015, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4804-5254","authenticated-orcid":false,"given":"Junbeom","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Surgery, Chungnam National University Hospital, Jung-gu, Daejeon 35015, Korea"},{"name":"Biomedical Research Institute, Chungnam National University Hospital, Jung-gu, Daejeon 35015, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Surgery, Chungnam National University Hospital, Jung-gu, Daejeon 35015, Korea"},{"name":"Department of Surgery and Research Institute for Medicinal Sciences, Chungnam National University College of Medicine, Jung-gu, Daejeon 35015, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: Clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1200\/JCO.2006.06.5664","article-title":"Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer","volume":"24","author":"Haffty","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tischkowitz, M., Brunet, J.S., B\u00e9gin, L.R., Huntsman, D.G., Cheang, M.C., Akslen, L.A., Nielsen, T.O., and Foulkes, W.D. (2007). Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer, 7.","DOI":"10.1186\/1471-2407-7-134"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.22618","article-title":"Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry","volume":"109","author":"Bauer","year":"2007","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1186\/bcr1622","article-title":"Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: Results from CALGB 9342","volume":"8","author":"Harris","year":"2006","journal-title":"Breast Cancer Res. BCR"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/cncr.22836","article-title":"Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: A single-institution compilation compared with the National Cancer Institute\u2019s Surveillance, Epidemiology, and End Results database","volume":"110","author":"Morris","year":"2007","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","article-title":"The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2","volume":"20","author":"Lakhani","year":"2002","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/jnci\/djg050","article-title":"Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer","volume":"95","author":"Foulkes","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","article-title":"The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes","volume":"13","author":"Carey","year":"2007","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1634\/theoncologist.2016-0067","article-title":"Biology and Management of Patients with Triple-Negative Breast Cancer","volume":"21","author":"Sharma","year":"2016","journal-title":"Oncologist"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1358\/dot.2010.46.9.1519020","article-title":"Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer","volume":"46","author":"Mani","year":"2010","journal-title":"Drugs Today"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","article-title":"Efficacy of eribulin in women with metastatic breast cancer: A pooled analysis of two phase 3 studies","volume":"148","author":"Twelves","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: Molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102925","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: The first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chen, S.-H., and Chang, J.-Y. (2019). New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174136"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-16-3055","article-title":"A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel with or without Everolimus in Patients with Stage II\/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67","volume":"23","author":"Mayer","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/annonc\/mdn395","article-title":"Platinum-based chemotherapy in triple-negative breast cancer","volume":"19","author":"Sirohi","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","article-title":"Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer","volume":"28","author":"Silver","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1359-6349(09)72076-2","article-title":"41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative","volume":"7","author":"Bhattacharyya","year":"2009","journal-title":"Ejc Suppl."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","article-title":"Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial","volume":"3","author":"Hahnen","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","article-title":"Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: A systematic review and meta-analysis","volume":"29","author":"Poggio","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3233\/BD-2010-0306","article-title":"BRCA1\/2 mutations and triple negative breast cancers","volume":"32","author":"Peshkin","year":"2010","journal-title":"Breast Dis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/0971-5851.73588","article-title":"Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results","volume":"31","author":"Goel","year":"2010","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1758835920958354","DOI":"10.1177\/1758835920958354","article-title":"Exploiting DNA repair defects in triple negative breast cancer to improve cell killing","volume":"12","author":"Lee","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/bjc.2014.554","article-title":"Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors","volume":"111","author":"Koczywas","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.21873\/anticanres.12604","article-title":"Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven\u00ae): Combination with Anticancer Agents of Differing Mechanisms","volume":"38","author":"Asano","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_27","first-page":"153","article-title":"Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions","volume":"22","author":"Pearson","year":"2001","journal-title":"Endocr. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"22986","DOI":"10.18632\/oncotarget.25184","article-title":"Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition","volume":"9","author":"Oba","year":"2018","journal-title":"Oncotarget"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"BSR20171357","DOI":"10.1042\/BSR20171357","article-title":"Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer","volume":"38","author":"Pakala","year":"2018","journal-title":"Biosci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13058-019-1204-2","article-title":"Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51","volume":"21","author":"Lee","year":"2019","journal-title":"Breast Cancer Res. BCR"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Gohr, K., Hamacher, A., Engelke, L.H., and Kassack, M.U. (2017). Inhibition of PI3K\/Akt\/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3695-5"},{"key":"ref_33","first-page":"6469","article-title":"Lenalidomide improvement of cisplatin antitumor efficacy on triple-negative breast cancer cells in vitro","volume":"15","author":"Yin","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11010-016-2894-8","article-title":"Synergistic action of cisplatin and echistatin in MDA-MB-231 breast cancer cells","volume":"427","author":"Czarnomysy","year":"2017","journal-title":"Mol. Cell. Biochem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"BSR20190362","DOI":"10.1042\/BSR20190362","article-title":"Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1\/2-AP-1 signaling pathway","volume":"39","author":"Tsai","year":"2019","journal-title":"Biosci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41419-019-1725-8","article-title":"Correction: 3-deazaneplanocin A protects against cisplatin-induced renal tubular cell apoptosis and acute kidney injury by restoration of E-cadherin expression","volume":"10","author":"Ni","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.neuro.2004.06.002","article-title":"Role of ERK activation in cisplatin-induced apoptosis in A172 human glioma cells","volume":"25","author":"Choi","year":"2004","journal-title":"Neurotoxicology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1742-4658.2009.07366.x","article-title":"ERK and cell death: Mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence","volume":"277","author":"Cagnol","year":"2010","journal-title":"FEBS J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/1098-2744(200012)29:4<219::AID-MC1004>3.0.CO;2-D","article-title":"Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal--regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines","volume":"29","author":"Cui","year":"2000","journal-title":"Mol. Carcinog."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00210-014-1071-4","article-title":"Lupeol inhibits proliferation and induces apoptosis of human pancreatic cancer PCNA-1 cells through AKT\/ERK pathways","volume":"388","author":"Liu","year":"2015","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_41","first-page":"73","article-title":"Cisplatin induced apoptosis of ovarian cancer A2780s cells by activation of ERK\/p53\/PUMA signals","volume":"33","author":"Song","year":"2018","journal-title":"Histol. Histopathol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/4\/547\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:55:13Z","timestamp":1760136913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/4\/547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["medicina58040547"],"URL":"https:\/\/doi.org\/10.3390\/medicina58040547","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2022,4,15]]}}}